Results Beyond Chemotherapy in Breast Cancer: PARP Inhibitors in BRCA Carriers

Targeted Drugs Outperform Chemotherapy in BRCA Carriers

Recent years have brought a major revolution in the treatment of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer. In the approach we now consider “standard,” the vast majority of our patients receive hormonal therapy in the first line together with targeted drugs known as CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib). These drugs keep the disease under control for a long time.

However, the question we encounter most often in oncology is: “What comes next when first-line treatment stops working?”

The traditional approach at this point was to switch to chemotherapy or try different hormonal drugs. But on December 13, 2025, npj Breast Cancer published a new study with groundbreaking results for patients carrying inherited (germline) BRCA mutations. The data show that, in this specific patient group, using PARP inhibitors rather than switching to chemotherapy can double the time the disease is kept at bay.

Study Details: Real-World Data Speak

This Italian multicenter study examined patients carrying BRCA1 or BRCA2 mutations whose disease had progressed after first-line treatment (CDK4/6 inhibitor + hormonal therapy), using data from 81 metastatic breast cancer patients . This was not a “clinical trial,” but an analysis of “real-world data” reflecting actual patient experiences in hospitals.

The researchers divided the second-line treatments received after initial treatment failure into four main groups and compared outcomes:

1. PARP Inhibitors (Oral targeted drugs)
2. Single-Agent Chemotherapy (Monochemotherapy)
3. Combination Chemotherapy (Polychemotherapy – more intensive regimens)
4. Hormonal Therapy Alone (Endocrine therapy)

Results: PARP Inhibitors Lead by a Wide Margin

The analysis showed that PARP inhibitors were unquestionably the most effective option after CDK4/6 inhibitors in patients carrying BRCA mutations.

How Do These Results Change Your Treatment Plan?

If you are receiving treatment for metastatic breast cancer, this study has two important messages for you:

• 1. The Importance of Genetic Testing (BRCA Testing) BRCA gene testing should be performed at some point during your disease course. If you carry this mutation, you have a treatment option (in pill form) that is much more effective than chemotherapy, with more manageable side effects. Your test result is the compass guiding your next move.
• 2. Treatment Sequencing: Earlier Use Is Better The study data show that, rather than “saving” PARP inhibitors, using them immediately in the second line after initial treatment (CDK4/6) ends provides the greatest success. Delaying the drug to later lines (3rd or 4th) may reduce its effectiveness by half.